This trial will study how well N-Acetyl Cysteine works in patients with Parkinson's disease by measuring dopamine function and clinical symptoms.
1 Primary · 1 Secondary · Reporting Duration: approximately 12 months ± 3 months
50 Total Participants · 0 Treatment Group
Primary Treatment: Treatment · No Placebo Group · Phase 2
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Pennsylvania | 100.0% |
Thomas Jefferson University, Marcus Institute of Integrative Health Centers | 100.0% |
Met criteria | 100.0% |
100.0% | |